BPBenjamin Philmus

Benjamin Philmus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benjamin Philmus has a total of 285 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Differential metabolite production underlies disruption of the cystic fibrosis airway microbiota by pathogens

    by Sydney M. Morabbi, Niladri Bhowmik, Shaz Sutherland, Evelyn A. Wylie, Reagan S. Decker, Akram Al Daerwish, Mercedes Pérez Pérez, Elizabeth Pascual, Erika I. Lutter, Benjamin Philmus, et al.

    Cystic fibrosis (CF) results in accumulation of mucus in the airways that promotes pathogen colonization, leading to respiratory exacerbations, lung failure, and death. The CF airway harbors a complex microbiota, including pathogens and oropharyngeal bacteria. Here, we reanalyzed 5,260 16S rRNA gene microbiota data sets to infer associations between members of the CF microbiota. We determined that pathogens are more likely to proliferate and dominate when present, while oropharyngeal bacteria are generally present at lower abundances. We found that higher diversity and increasing numbers of pairwise associations between bacteria were positively correlated with lung function. In contrast, dominance of the microbiota by pathogens was associated with loss of lung function. We determined that pathogens are largely negatively associated with each other and oropharyngeal bacteria, suggesting they are antagonistic toward other bacteria. As a first test of this hypothesis, we cultured 1,597 isolates from 96 people with CF and performed 12,542 coculture assays against eight representative pathogens and oropharyngeal bacteria, finding 23% of interactions resulted in inhibition. Among our isolates, Pseudomonas were the most inhibitory, but we observed variable activity between different isolates. We further found Pseudomonas aeruginosa isolates, even those from the same donor and time point, exhibited significant differences in their metabolome and bioactivity profiles that correlated with acquisition of mutations. Together, our results suggest that pathogens may disrupt the CF microbiota and proliferate in part through bioactive metabolite production. Furthermore, these data highlight that characterizing multiple isolates is necessary to capture the full landscape of chemically mediated interactions within microbiomes. IMPORTANCE: The cystic fibrosis (CF) airway harbors a complex microbiota, including oropharyngeal bacteria and opportunistic pathogens that establish chronic infections. We found that microbiota diversity is correlated with health and that a pathogen-dominated microbiota is associated with low lung function. We then inferred potential microbial interactions by determining abundance associations between CF genera, which suggested that pathogens antagonize other bacteria. To test this prediction, we cultured bacteria from people with CF and performed thousands of coculture assays, finding that approximately one-quarter of interactions resulted in growth inhibition. Pseudomonas broadly inhibited other members of the CF airway microbiota. However, we observed marked variability in bioactivity and metabolite profiles of Pseudomonas aeruginosa isolates, even from the same donor at the same time. Our results suggest that pathogens disrupt the CF microbiota, possibly through bioactive metabolite production, and that characterizing multiple isolates is necessary to capture the complete picture of interactions in these communities.

  • Open Access

    Differential Metabolite Production Underlies Disruption of the Cystic Fibrosis Airway Microbiota by Pathogens

    by Sydney M. Morabbi, Niladri Bhowmik, Shaz Sutherland, Evelyn A. Wylie, Reagan S. Decker, Akram Al Daerwish, Mercedes Pérez Pérez, Elizabeth Pascual, Erika I. Lutter, Benjamin Philmus, et al.

    Cystic fibrosis (CF) is a multisystem disease characterized by the accumulation of mucus in the airways that promotes pathogen colonization, leading to respiratory exacerbations, lung failure, and death. Culture-independent approaches have revealed that the CF airway harbors a complex microbiota, including opportunistic pathogens and bacteria that colonize the oropharynx. Here, we reanalyzed 5,260 16S rRNA gene microbiota datasets to infer ecological associations between members of the CF microbiota. We determined that pathogens are more likely to proliferate and dominate when present, while oropharyngeal bacteria are more likely to form persistent communities. Further, we found higher diversity and increasing numbers of inferred interactions were positively associated with lung function. In contrast, pathogens were negatively associated both with each other and with oropharyngeal bacteria, suggesting that they may disrupt the microbiota. To validate these predictions, we cultured 1,597 bacterial isolates from 96 people with CF and performed 12,542 coculture assays against eight representative CF pathogenic and oropharyngeal bacteria. 23% of these interactions resulted in growth inhibition. While Pseudomonas isolates were, on average, the most inhibitory, we observed variable activity among isolates. We then confirmed that Pseudomonas aeruginosa isolates, even those from the same donor and timepoint, exhibited significant differences in their metabolome and bioactivity profiles that correlated with acquisition of mutations. Together, our results suggest that pathogens may disrupt the CF microbiota and bloom in part through differential metabolite production. Furthermore, these data highlight that characterizing multiple isolates is necessary to capture the full landscape of chemically mediated interactions within microbial communities. Importance: The cystic fibrosis (CF) airway harbors a complex microbiota, including oropharyngeal bacteria and opportunistic pathogens that establish chronic infections and cause lung failure. We confirmed that microbiota diversity is correlated with health and that a pathogen-dominated microbiota is associated with reduced lung function. We then inferred microbial interactions, which suggested that pathogens are able to disrupt the microbiota. To validate these predictions, we cultured bacterial isolates from people with CF and performed thousands of coculture assays, finding that approximately one-quarter of interactions resulted in growth inhibition. Pseudomonas broadly inhibited other members of the CF airway microbiota. However, we observed marked variability in bioactivity and metabolite profiles of Pseudomonas aeruginosa isolates, even from the same donor at the same time. Our results suggest that pathogens disrupt the CF microbiota, possibly through bioactive metabolite production, and that characterizing multiple isolates is necessary to capture the complete picture of interactions in these communities.

  • Insights into the Biosynthesis of Kibdelomycin and Amycolamicin from Comparative Biosynthetic Gene Cluster Analysis and Precursor Incorporation Studies

    by Marina Sánchez-Hidalgo, José Miguel Quesada, Daniel Oves-Costales, Jonah Fine, Jesús Martín, Fernando Román-Hurtado, Ryann Callaghan, Vanessa Raab, Jillian Scarpanito, John B. Perkins, et al.

    Kibdelomycin and amycolamicin are identical antibiotics produced by Kibdelosporangium banguiense CA-240109 and Amycolatopsis sp. MK575-fF5, respectively. They are broad-spectrum antibiotics showing potent activity against antibiotic-resistant Gram-positive bacteria. These compounds inhibit DNA gyrase subunit B (GyrB) and topoisomerase IV (ParE) by a unique U-shaped multicontact binding mode and have no cross-resistance to known antibiotics. Kibdelomycin represents a promising scaffold for developing new antibiotics, but its poor production, structural complexity, and chemical stability limit its chemical modification. In this work, we describe the improvement of kibdelomycin production via strain mutagenesis and the elucidation of kibdelomycin biosynthesis using isotope-labeled feeding experiments and sequencing of the kibdelomycin and amycolamicin biosynthetic gene clusters (BGCs), which are similar but not identical. These studies provide avenues for structure-guided biosynthetic analogue development as well as material for chemical modification.


  • Open Access

    Green genes from blue greens: challenges and solutions to unlocking the potential of cyanobacteria in drug discovery

    by Benjamin Philmus, Nicole E. Avalon, Yousong Ding, Drew T. Doering, Alessandra S. Eustáquio, William H. Gerwick, Hendrik Luesch, Jimmy Orjala, Shaz Sutherland, Arnaud Taton, et al.

    Cyanobacteria are prolific producers of bioactive natural products. In this article, we outline some challenges faced in exploiting cyanobacteria for drug discovery, current solutions, and pathways forward to fully explore them for drug discovery.


  • Crystal Structure, Modeling, and Identification of Key Residues Provide Insights into the Mechanism of the Key Toxoflavin Biosynthesis Protein ToxD

    by Savannah F. Justen, Michael K. Fenwick, Kyle K. Axt, James A. Cherry, Steven E. Ealick, Benjamin Philmus

    Toxoflavin, a toxic secondary metabolite produced by a variety of bacteria, has been implicated as a causative agent in food poisoning and a virulence factor in phytopathogenic bacteria. This toxin is produced by genes encoded in the tox operon in Burkholderia glumae, in which the encoded protein, ToxD, was previously characterized as essential for toxoflavin production. To better understand the function of ToxD in toxoflavin biosynthesis and provide a basis for future work to develop inhibitors of ToxD, we undertook the identification of structurally and catalytically important amino acid residues through a combination of X-ray crystallography and site directed mutagenesis. We solved the structure of BgToxD, which crystallized as a dimer, to 1.8 Å resolution. We identified a citrate molecule in the putative active site. To investigate the role of individual residues, we used Pseudomonas protegens Pf-5, a BL1 plant protective bacterium known to produce toxoflavin, and created mutants in the ToxD-homologue PFL1035. Using a multiple sequence alignment and the BgToxD structure, we identified and explored the functional importance of 12 conserved residues in the putative active site. Eight variants of PFL1035 resulted in no observable production of toxoflavin. In contrast, four ToxD variants resulted in reduced but detectable toxoflavin production suggesting a nonessential role. The crystal structure and structural models of the substrate and intermediate bound enzyme provide a molecular interpretation for the mutagenesis data.


  • Open Access

    Formation of the Ureido Bond in Anabaenopeptins by ApnA from Planktothrix agardhii CYA 126/8.

    by Benjamin Philmus, Thomas Hemscheidt

    The process leading to the formation of the ureido bond linking lysine and tyrosine/arginine, respectively, in the anabaenopeptins has been reconstituted in vitro. Trapping experiments suggest that an enzyme bound lysine -carbamic acid is an intermediate. Labeling experiments with 18O-bicarbonate suggest that a carbamic acid mixed anhydride is formed from the tyrosine/arginine thioester and subsequently rearranged to yield the ureido-dipeptide.

  • Identification, Heterologous Expression, and Characterization of the Tolypodiol Biosynthetic Gene Cluster through an Integrated Approach

    by Daniel Back, Timothy J. O’dOnnell, Kyle K. Axt, Joshua R. Gurr, Juan M. Vanegas, Philip G. Williams, Benjamin Philmus

    Cyanobacteria are tremendous producers of biologically active natural products, including the potent anti-inflammatory compound tolypodiol. However, linking biosynthetic gene clusters with compound production in cyanobacteria has lagged behind that in other bacterial genera. Tolypodiol is a meroterpenoid originally isolated from the cyanobacterium HT-58-2. Here we describe the identification of the tolypodiol biosynthetic gene cluster through heterologous expression in Anabaena and in vitro protein assays of a methyltransferase found in the tolypodiol biosynthetic gene cluster. We have also identified similar biosynthetic gene clusters in cyanobacterial and actinobacterial genomes, suggesting that meroterpenoids with structural similarity to the tolypodiols may be synthesized by other microbes. We also report the identification of two new analogs of tolypodiol that we have identified in both the original and heterologous producer. This work further illustrates the usefulness of Anabaena as a heterologous expression host for cyanobacterial compounds and how integrated approaches can help to link natural product compounds with their producing biosynthetic gene clusters.


  • Metabolomics-Guided Discovery, Isolation, Structure Elucidation, and Bioactivity of Myropeptins C–E from Myrothecium inundatum

    by Annika Jagels, Donovon A. Adpressa, Elizabeth N. Kaweesa, Mark McCauley, Benjamin Philmus, James A. Strother, Sandra Loesgen

    The saprotrophic filamentous fungus Myrotheciuminundatum represents a chemically underexplored ascomycetewith a high numberof putative biosynthetic gene clusters in its genome. Here, we presentnew linear lipopeptides from nongenetic gene activation experimentsusing nutrient and salt variations. Metabolomics studies revealedfour myropeptins, and structural analyses by NMR, HRMS, Marfey'sanalysis, and ECD assessment for their helical properties establishedtheir absolute configuration. A myropeptin biosynthetic gene clusterin the genome was identified. The myropeptins exhibit general nonspecifictoxicity against all cancer cell lines in the NCI-60 panel, larvalzebrafish with EC50 concentrations of 5-30 & mu;M,and pathogenic bacteria and fungi (MICs of 4-32 & mu;g/mLagainst multidrug-resistant S. aureus and C. auris). In vitro hemolysis, cell viability,and ionophore assays indicate that the myropeptins target mitochondrialand cellular membranes, inducing cell depolarization and cell death.The toxic activity is modulated by the length of the lipid side chain,which provides valuable insight into their structure-activityrelationships.


  • Open Access

    Identification, heterologous expression, and characterization of the tolypodiol biosynthetic gene cluster through an integrated approach.

    by Daniel Back, Timothy J. O'DOnnell, Kyle Axt, Joshua Gurr, Juan Vanegas, Philip Williams, Benjamin Philmus

    Cyanobacteria are tremendous producers of biologically active natural products including the potent anti-inflammatory compound tolypodiol. However, linking biosynthetic gene clusters with compound production in cyanobacteria has lagged behind other bacterial genera. Tolypodiol is a meroterpenoid originally isolated from the cyanobacterium HT-58-2. Here we describe the identification of the tolypodiol biosynthetic gene cluster through heterologous expression in Anabaena, and in vitro protein assays of a methyltransferase found in the tolypodiol biosynthetic gene cluster. We have also identified similar biosynthetic gene clusters in cyanobacterial and actinobacterial genomes suggesting that meroterpenoids with structural similarity to the tolypodiols may be synthesized by other microbes. We also report the identification of two new analogs of tolypodiol that we have identified in both the original and heterologous producer. This work further illustrates the usefulness of Anabaena as a heterologous expression host for cyanobacterial compounds and how integrated approaches can help link natural product compounds with their producing biosynthetic gene clusters.


  • Acarbose May Function as a Competitive Exclusion Agent for the Producing Bacteria

    by Samuel Tanoeyadi, Takeshi Tsunoda, Takuya Ito, Benjamin Philmus, Taifo Mahmud

    Acarbose is a well-known microbial specialized metabolite used clinically to treat type 2 diabetes. This natural pseudo-oligosaccharide (PsOS) shows potent inhibitory activity toward various glycosyl hydrolases, including α-glucosidases and α-amylases. While acarbose and other PsOSs are produced by many different bacteria, their ecological or biological role in microbial communities is still an open question. Here, we show that several PsOS-producing actinobacteria, i.e., Actinoplanes sp. SE50/110 (acarbose producer), Streptomyces glaucescens GLA.O (acarbose producer), and Streptomyces dimorphogenes ATCC 31484 (trestatin producer), can grow in the presence of acarbose, while the growth of the non-PsOS-producing organism Streptomyces coelicolor M1152 was suppressed when starch is the main source of energy. Further investigations using recombinant α-amylases from S. coelicolor M1152 and the PsOS-producing actinobacteria revealed that the S. coelicolor α-amylase was inhibited by acarbose, whereas those from the PsOS-producing bacteria were not inhibited by acarbose. Bioinformatic and protein modeling studies suggested that a point mutation in the α-amylases of the PsOS-producing actinobacteria is responsible for the resistance of those enzymes toward acarbose. Converting the acarbose-resistant α-amylase AcbE to its A304H variant diminished its acarbose-resistance property. Taken together, the results suggest that acarbose is used by the producing bacteria as a competitive exclusion agent to suppress the growth of other microorganisms in their natural environment, while the producing organisms equip themselves with α-amylase variants that are resistant to acarbose.